<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349618</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Oneyear longitudinal study on biomarkers of blood-brain barrier permeability in COVID-19 patients.</ArticleTitle><Pagination><StartPage>22735</StartPage><MedlinePgn>22735</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22735</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73321-y</ELocationID><Abstract><AbstractText>The pathophysiology behind neurological and cognitive sequelae of COVID-19 may be related to dysfunction of the blood-brain barrier (BBB) and previous research indicate transient neuronal injury and glial activation. The aim of this study was to investigate if COVID-19 is related to increased BBB permeability by analyzing leakage of biomarkers such as astrocyte-derived extracellular vesicles (EVs) and S100B. We also investigated whether levels of these biomarkers correlated with self-reported symptoms that persisted &gt; 2 months. The samples in this 1-year follow-up study came from an ongoing longitudinal study of unvaccinated patients hospitalized for COVID-19 at Danderyd University Hospital, Stockholm, Sweden, between April and June 2020. Blood samples were collected at baseline and 4, 8, and 12 months after hospitalization. Information on self-reported clinical symptoms was collected at follow-up visits. A total of 102 patients were enrolled, and 47 completed all follow-up measurements. Peak levels of both biomarkers were observed at 4 months in the subset of 55 patients who were measured at this timepoint. At 12 months, the biomarkers had returned to baseline levels. The biomarkers were not correlated with any of the long-term self-reported symptoms. COVID-19 is associated with transient increased BBB permeability, shown by elevated levels of astrocyte biomarkers in plasma. However, these levels return to baseline 12 months post-infection and do not correlate with long-term symptoms. Further research is needed to unravel the underlying mechanisms causing long-term symptoms in COVID-19 patients.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wallensten</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Academic Primary Health Care Centre, Region Stockholm, Solnavägen 1E, Box 45436, 104 31, Stockholm, Sweden. Johanna.wallensten@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, 18288, Stockholm, Sweden. Johanna.wallensten@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havervall</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, 18288, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Uppsala University, 75185, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Åsberg</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, 18288, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borg</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, 18288, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nager</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Family Medicine and Primary Health Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 17177, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thålin</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, 18288, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mobarrez</LastName><ForeName>Fariborz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Uppsala University, 75185, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579160">S100B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="Y">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064568" MajorTopicYN="N">S100 Calcium Binding Protein beta Subunit</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349618</ArticleId><ArticleId IdType="pmc">PMC11442946</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73321-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73321-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groff, D. et al. Short-term and long-term rates of Postacute Sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw. Open.4, e2128568. 10.1001/jamanetworkopen.2021.28568 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban, F. et al. Fatigue and cognitive impairment in Post-COVID-19 syndrome: A systematic review and meta-analysis. Brain Behav. Immun.101, 93–135. 10.1016/j.bbi.2021.12.020 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Yang, W., Chen, F. &amp; Cui, L. COVID-19 and cognitive impairment: Neuroinvasive and blood–brain barrier dysfunction. J. Neuroinflammation. 19, 222. 10.1186/s12974-022-02579-8 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9450840</ArticleId><ArticleId IdType="pubmed">36071466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto, V. et al. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front. Immunol.13, 1070379. 10.3389/fimmu.2022.1070379 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798841</ArticleId><ArticleId IdType="pubmed">36591311</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke, J. et al. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol.19, 919–929. 10.1016/s1474-4422(20)30308-2 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med.21810.1084/jem.20202135 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, I. H. et al. Neuropathological features of Covid-19. N Engl. J. Med.383, 989–992. 10.1056/NEJMc2019373 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci.24, 168–175. 10.1038/s41593-020-00758-5 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay, M. E., Madore, C., Bordeleau, M., Tian, L. &amp; Verkhratsky, A. Neuropathobiology of COVID-19: The role for Glia. Front. Cell. Neurosci.14, 592214. 10.3389/fncel.2020.592214 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7693550</ArticleId><ArticleId IdType="pubmed">33304243</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar, M. A. et al. Neurological and Neuropsychological Changes Associated with SARS-CoV-2 infection: New observations, New mechanisms. Neuroscientist. 107385842098410610.1177/1073858420984106 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33393420</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi, M. M., Gong, C., Xu, Y. G., Chang, Y. &amp; Shi, H. Factors controlling permeability of the blood-brain barrier. Cell. Mol. Life Sci.73, 57–77. 10.1007/s00018-015-2050-8 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11108286</ArticleId><ArticleId IdType="pubmed">26403789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, B., Huang, S. &amp; Yin, L. The cytokine storm and COVID-19. J. Med. Virol.93, 250–256. 10.1002/jmv.26232 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Serlin, Y., Shelef, I., Knyazer, B. &amp; Friedman, A. Anatomy and physiology of the blood-brain barrier. Semin Cell. Dev. Biol.38, 2–6. 10.1016/j.semcdb.2015.01.002 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397166</ArticleId><ArticleId IdType="pubmed">25681530</ArticleId></ArticleIdList></Reference><Reference><Citation>Keaney, J. &amp; Campbell, M. The dynamic blood-brain barrier. Febs J.282, 4067–4079. 10.1111/febs.13412 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26277326</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. R., Liu, J. C., Bao, J. S., Bai, Q. Q. &amp; Wang, G. Q. Interaction of Microglia and astrocytes in the neurovascular unit. Front. Immunol.11, 1024. 10.3389/fimmu.2020.01024 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362712</ArticleId><ArticleId IdType="pubmed">32733433</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebner, S. et al. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol.135, 311–336. 10.1007/s00401-018-1815-1 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6781630</ArticleId><ArticleId IdType="pubmed">29411111</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiera, G., Di Liegro, C. M., Schirò, G. &amp; Sorbello, G. Di Liegro, I. involvement of astrocytes in the formation, maintenance, and function of the blood-brain barrier. Cells. 1310.3390/cells13020150 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10813980</ArticleId><ArticleId IdType="pubmed">38247841</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp, J. &amp; Hol, E. M. GFAP in health and disease. Prog Neurobiol.93, 421–443. 10.1016/j.pneurobio.2011.01.005 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21219963</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiry-Moghaddam, M. &amp; Ottersen, O. P. The molecular basis of water transport in the brain. Nat. Rev. Neurosci.4, 991–1001. 10.1038/nrn1252 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14682361</ArticleId></ArticleIdList></Reference><Reference><Citation>Thelin, E. P., Nelson, D. W. &amp; Bellander, B. M. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir. (Wien). 159, 209–225. 10.1007/s00701-016-3046-3 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241347</ArticleId><ArticleId IdType="pubmed">27957604</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandebroek, A. &amp; Yasui, M. Regulation of AQP4 in the Central Nervous System. Int. J. Mol. Sci.2110.3390/ijms21051603 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7084855</ArticleId><ArticleId IdType="pubmed">32111087</ArticleId></ArticleIdList></Reference><Reference><Citation>Puffer, R. C. et al. Plasma extracellular vesicles as a source of biomarkers in traumatic brain injury. J. Neurosurg. 1–8. 10.3171/2020.4.Jns20305 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32707544</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharbi, T., Zhang, Z. &amp; Yang, G. Y. The function of astrocyte mediated Extracellular vesicles in Central Nervous System diseases. Front. Cell. Dev. Biol.8, 568889. 10.3389/fcell.2020.568889 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593543</ArticleId><ArticleId IdType="pubmed">33178687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindblad, C. et al. Influence of blood-brain Barrier Integrity on brain protein biomarker clearance in severe traumatic brain Injury: A longitudinal prospective study. J. Neurotrauma. 37, 1381–1391. 10.1089/neu.2019.6741 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249468</ArticleId><ArticleId IdType="pubmed">32013731</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner, J. et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci.810.1186/1471-2202-8-2 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1769505</ArticleId><ArticleId IdType="pubmed">17199889</ArticleId></ArticleIdList></Reference><Reference><Citation>Undén, J., Ingebrigtsen, T. &amp; Romner, B. Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC Med.11, 50. 10.1186/1741-7015-11-50 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3621842</ArticleId><ArticleId IdType="pubmed">23432764</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal, A. et al. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J. Neurotrauma. 30, 946–957. 10.1089/neu.2012.2579 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684103</ArticleId><ArticleId IdType="pubmed">23190274</ArticleId></ArticleIdList></Reference><Reference><Citation>Aceti, A. et al. Serum S100B protein as a marker of severity in Covid-19 patients. Sci. Rep.10, 18665. 10.1038/s41598-020-75618-0 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596559</ArticleId><ArticleId IdType="pubmed">33122776</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, R. C. et al. Brain damage serum biomarkers induced by COVID-19 in patients from northeast Brazil. J. Neurovirol. 1–7. 10.1007/s13365-023-01119-1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888322</ArticleId><ArticleId IdType="pubmed">36719594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, H. et al. Circulating markers of Neutrophil Extracellular traps are of Prognostic Value in patients with COVID-19. Arterioscler. Thromb. Vasc Biol.41, 988–994. 10.1161/atvbaha.120.315267 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837697</ArticleId><ArticleId IdType="pubmed">33267662</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt, F. A. et al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv.5, 756–759. 10.1182/bloodadvances.2020003968 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosell, A. et al. Patients with COVID-19 have elevated levels of circulating Extracellular Vesicle tissue factor activity that is Associated with severity and mortality-brief report. Arterioscler. Thromb. Vasc Biol.41, 878–882. 10.1161/atvbaha.120.315547 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837685</ArticleId><ArticleId IdType="pubmed">33267656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobarrez, F. et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb. Res.125, e110–116. 10.1016/j.thromres.2009.10.006 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19939440</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli, A. et al. Self-reported olfactory and taste disorders in patients with severe Acute Respiratory Coronavirus 2 infection: a cross-sectional study. Clin. Infect. Dis.71, 889–890. 10.1093/cid/ciaa330 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184514</ArticleId><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>de Erausquin, G. A. et al. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement.17, 1056–1065. 10.1002/alz.12255 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10431934</ArticleId><ArticleId IdType="pubmed">33399270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair, A. S. et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of Coronavirus Disease 2019: a review. JAMA Neurol.77, 1018–1027. 10.1001/jamaneurol.2020.2065 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>The, L. Facing up to long COVID. Lancet. 396, 1861. 10.1016/s0140-6736(20)32662-3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834723</ArticleId><ArticleId IdType="pubmed">33308453</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. &amp; Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis.22, e102–e107. 10.1016/s1473-3099(21)00703-9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg, N. et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 95, e1754–e1759. 10.1212/wnl.0000000000010111 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg, N. et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine. 70, 103512. 10.1016/j.ebiom.2021.103512 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 90, 870–881. 10.1136/jnnp-2018-320106 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon, P. J. et al. Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J. Neurotrauma. 32, 527–533. 10.1089/neu.2014.3635 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394160</ArticleId><ArticleId IdType="pubmed">25264814</ArticleId></ArticleIdList></Reference><Reference><Citation>Brozzi, F., Arcuri, C., Giambanco, I. &amp; Donato, R. S100B protein regulates astrocyte shape and Migration via Interaction with src kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH. J. Biol. Chem.284, 8797–8811. 10.1074/jbc.M805897200 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659238</ArticleId><ArticleId IdType="pubmed">19147496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasič, E. et al. Time-dependent uptake and trafficking of vesicles capturing extracellular S100B in cultured rat astrocytes. J. Neurochem. 139, 309–323. 10.1111/jnc.13754 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27488079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloutier, N. et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: The microparticle-associated immune complexes. EMBO Mol. Med.5, 235–249. 10.1002/emmm.201201846 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569640</ArticleId><ArticleId IdType="pubmed">23165896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobarrez, F. et al. Microparticles in the blood of patients with SLE: size, content of mitochondria and role in circulating immune complexes. J. Autoimmun.102, 142–149. 10.1016/j.jaut.2019.05.003 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31103269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallone, R. et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: Position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol.163, 33–49. 10.1111/j.1365-2249.2010.04272.x (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010910</ArticleId><ArticleId IdType="pubmed">20939860</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, M., Hou, J., Xu, M., Li, S. &amp; Yang, B. Aquaporins in nervous system. Adv. Exp. Med. Biol.1398, 99–124. 10.1007/978-981-19-7415-1_7 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36717489</ArticleId></ArticleIdList></Reference><Reference><Citation>Mader, S. &amp; Brimberg, L. Aquaporin-4 Water Channel in the brain and its implication for Health and Disease. Cells. 810.3390/cells8020090 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6406241</ArticleId><ArticleId IdType="pubmed">30691235</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlén, M. et al. Proteomics. Tissue-based map of the human proteome. Science. 347, 1260419. 10.1126/science.1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>